Study of niraparib and abemaciclib for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a combination of two targeted drugs, niraparib and abemaciclib, for people with ovarian, fallopian tube, or primary peritoneal cancer that has come back after at least two prior chemotherapies. It may be an option if you have no standard treatments left and your cancer still responds to platinum-based chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have ovarian, fallopian tube, or primary peritoneal cancer that has returned and no cure is available
- You must have had at least 2 prior chemotherapy treatments that worked for more than 6 months
- You must be willing to provide a tumor sample (or have a biopsy) and undergo blood tests for genetic testing
- Your cancer must still respond to platinum-based chemotherapy (or you have progressed while on a PARP inhibitor)
- You must be in good overall health (ECOG score 0 or 1) and have adequate blood counts and organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether niraparib works better when combined with bevacizumab after chemotherapy and surgery for advanced ovarian, fallopian tube, or peritoneal cancer. If you qualify, you may help researchers find a treatment plan that controls the cancer for longer.
This trial tests whether niraparib, taken after surgery, works better when combined with bevacizumab in people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have no visible tumor left. It also aims to see if this approach helps prevent the cancer from coming back.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This trial tests whether a different starting dose (and adjustments) of niraparib can help people with advanced ovarian (or related) cancer stay on treatment without as many dose interruptions. It’s designed for people who have already finished first-line chemotherapy and whose cancer responded.
This study looks at how well niraparib works as maintenance therapy for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have already responded to initial chemotherapy. It aims to gather real-world data on the treatment's effectiveness and safety.
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.